Jennifer A. Dantzer

Mar 12, 2024 | healio.com | Richard Gawel |Kristen Dowd |Jennifer A. Dantzer

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Cow’s milk allergy is the most common food allergy in young children. Patients treated for 24 months could tolerate more unheated milk than the patients who were treated for 12 months.

Oct 20, 2023 | healio.com | Richard Gawel |Kristen Dowd |Scott H. Sicherer |Jennifer A. Dantzer

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 78.9% of the per-protocol group ingested the full 4,443 mg of peanut protein at month 36. Although all of the children experienced reactions, none required epinephrine.

Apr 1, 2023 | social.cn1699.com | Jennifer A. Dantzer |Jay Lieberman

Source/Disclosures Disclosures: Kim reports serving on the scientific advisory board for ALK-Abelló, DBV Technologies, Kenota Health and Ukko Inc.; being a consultant for Allergenis, Allergy Therapeutics Ltd., Belhaven Pharma, Duke Clinical Research Institute, Genentech and Nutricia; and receiving grant support from the NIH National Institute of Allergy and Infectious Diseases and Food Allergy Research and Education. Please see the study for all other authors’ relevant financial disclosures.

Mar 31, 2023 | healio.com | Richard Gawel |Kristen Dowd |Jennifer A. Dantzer |Jay Lieberman

Jennifer A. Dantzer, MD, MHS To date, multiple modalities of immunotherapy for peanut food allergy have been investigated, including oral, SLIT, epicutaneous and subcutaneous immunotherapy. There is currently one FDA-approved product for peanut OIT. While OIT may be efficacious, there is also a risk for potentially severe adverse side effects, as well as the need for frequent office visits. Therefore, it is important to continue to pursue alternative options. One such option is SLIT.

Feb 1, 2023 | newsbeezer.com | Jennifer A. Dantzer

Health0 Views February 01, 2023 3 min read Source/Disclosures Disclosure: Anagnostou reports that he serves as principal investigator for Aimmune Therapeutics’ Phase 3 peanut OIT trials and receives institutional funding from DBV Technologies and serves on the Advisory Board. The other authors report no relevant financial information. We could not process your request. Please try again later. If this issue persists, please contact [email protected].